Wnt/β-catenin signaling in cancers and targeted therapies  

作　　者：Fanyuan Yu Changhao Yu Feifei Li Yanqin Zuo Yitian Wang Lin Yao Chenzhou Wu Chenglin Wang Ling Ye 

机构地区：[1]State Key Laboratory of Oral Diseases&National Clinical Research Center for Oral Diseases,West China Hospital of Stomatology,Sichuan University,Chengdu,China [2]Department of Endodontics,West China Stomatology Hospital,Sichuan University,Chengdu,China [3]Department of Head and Neck Oncology,West China Hospital of Stomatology,Sichuan University,Chengdu,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第9期2770-2793,共24页信号转导与靶向治疗（英文）

基　　金：The work is supported by the National Natural Science Foundation of China 81825005;State Key Laboratory of Oral Diseases SKLOD202007(L.Y.).

摘　　要：Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental cancer models of animals.Aberrant activation of Wnt/β-catenin signaling is tightly linked with the increment of prevalence,advancement of malignant progression,development of poor prognostics,and even ascendence of the cancer-associated mortality.Early experimental investigations have proposed the theoretical potential that efficient repression of this signaling might provide promising therapeutic choices in managing various types of cancers.Up to date,many therapies targeting Wnt/β-catenin signaling in cancers have been developed,which is assumed to endow clinicians with new opportunities of developing more satisfactory and precise remedies for cancer patients with aberrant Wnt/β-catenin signaling.

关 键 词：CANCERS MORTALITY INCREMENT 

分 类 号：R730.5[医药卫生—肿瘤]